Co-Diagnostics announced on March 20, 2026, that its Indian joint venture CoSara Diagnostics has signed an agreement to significantly broaden its commercial and distribution territory across South Asia. The expansion now includes Bangladesh, Pakistan, Nepal, and Sri Lanka in addition to existing markets, increasing the addressable market in the region to an estimated $13 billion. This move supports the planned commercialization of the company's PCR Pro® point-of-care instrument and SARAGENE® tests (subject to regulatory approvals). CoSara will evaluate regulatory pathways, establish distribution channels, host a virtual distributor session in Q2 2026, and hold an in-person training event later in the summer. The announcement, released early in the trading day, directly catalyzed heavy buying interest in the small-cap molecular diagnostics name, pushing the stock from the prior close of $2.65 sharply higher with intraday gains reaching around 31% amid elevated volume. The news builds on recent positive developments, including regained Nasdaq compliance in mid-March and ongoing efforts to advance its point-of-care PCR platform.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.